Drug Manufacturing

Novartis to build fourth US radioligand therapy facility in Florida

Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.

MediLink and Roche announce exclusive licensing agreement for YL201c

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug conjugate (ADC) targeting B7H3 in various solid tumour types.

Samsung Biologics to acquire Human Genome Sciences

Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from GSK as part of its plan to expand manufacturing capabilities in the US.

J&J receives FDA approval for lung cancer therapy

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

EC approves Incyte’s Minjuvi combo for follicular lymphoma

The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) who have received a minimum of one systemic therapy line.

Alnylam plans $250m investment in Norton manufacturing facility, US

Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.

Zealand Pharma and OTR to develop metabolic disease therapeutics

Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies for several targets in metabolic diseases.

Viatris signs agreements with Biocon on $815m stake sale

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.

Made Scientific and Cellergy partner to advance CLG-001

Made Scientific and Cellergy Therapeutics have formed a manufacturing partnership to advance the latter’s CLG-001 mitochondrial therapy toward first-in-human studies.